Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021

Rhea-AI Summary

Avid Bioservices, Inc. (NASDAQ:CDMO) will report its financial results for Q2 of fiscal year 2022 on December 7, 2021, after market close. A conference call and webcast will take place at 1:30 PM PT (4:30 PM ET) on the same day, where senior management will discuss Q1 results and corporate developments. Avid is a dedicated contract development and manufacturing organization specializing in biologics, with nearly 30 years of experience in the biotechnology sector. The company offers a wide range of services, including CGMP manufacturing and process development.

TUSTIN, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2022 on December 7, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).   Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

FAQ

When will Avid Bioservices report its Q2 financial results for fiscal year 2022?

Avid Bioservices will report its Q2 financial results on December 7, 2021, after market close.

What time is Avid Bioservices' conference call regarding financial results?

The conference call will occur at 1:30 PM Pacific Time (4:30 PM Eastern Time) on December 7, 2021.

What services does Avid Bioservices provide?

Avid Bioservices specializes in development and CGMP manufacturing of biologics, including process development and drug substance manufacturing.